Montag & Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Montag & Associates’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.95K	Hold	34	–	–	﹤0.01%	870
2026 Q1	$1.92K	Hold	34	–	–	﹤0.01%	848
2025 Q4	$2.02K	Hold	34	–	–	﹤0.01%	865
2025 Q3	$1.84K	Hold	34	–	–	﹤0.01%	932
2025 Q2	$1.87K	Hold	34	–	–	﹤0.01%	853
2025 Q1	$2.4K	Hold	34	–	–	﹤0.01%	880
2024 Q4	$2.23K	Hold	34	–	–	﹤0.01%	882
2024 Q3	$2.39K	Hold	34	–	–	﹤0.01%	905
2024 Q2	$2.8K	Hold	34	–	–	﹤0.01%	856
2024 Q1	$2.97K	Hold	34	–	–	﹤0.01%	849
2023 Q4	$3.28K	Hold	34	–	–	﹤0.01%	848
2023 Q3	$3.01K	Hold	34	–	–	﹤0.01%	831
2023 Q2	$2.95K	Hold	34	–	–	﹤0.01%	849
2023 Q1	$3.31K	Hold	34	–	–	﹤0.01%	845
2022 Q4	$3.52K	Hold	34	–	–	﹤0.01%	844
2022 Q3	$3K	Hold	34	–	–	﹤0.01%	799
2022 Q2	$3K	Hold	34	–	–	﹤0.01%	758
2022 Q1	$3K	Hold	34	–	–	﹤0.01%	769
2021 Q4	$3K	Hold	34	–	–	﹤0.01%	780
2021 Q3	$3K	Hold	34	–	–	﹤0.01%	776
2021 Q2	$3K	Hold	34	–	–	﹤0.01%	770
2021 Q1	$3K	Hold	34	–	–	﹤0.01%	775
2020 Q4	$3K	Buy	+34	New	+$2.7K	﹤0.01%	756

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Montag & Associates's BMRN Position: Q2 2026 in Review

Montag & Associates held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 34 shares worth $1.95K. The position accounts for ﹤0.01% of the portfolio, ranked #870.

Montag & Associates first reported a position in BMRN in Q4 2020 and has held it in 23 quarters since. The position peaked at $3.52K in Q4 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Montag & Associates held 34 shares of BioMarin Pharmaceuticals worth $1.95K as of Q2 2026.
Montag & Associates left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Montag & Associates's portfolio in Q2 2026, its #870 holding.
Montag & Associates first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
Montag & Associates's BioMarin Pharmaceuticals position peaked at $3.52K in Q4 2022.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Montag & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.